Inscobee Inc.'s Form 4 filing
Apimeds Pharmaceuticals US, Inc. (APUS) · filed May 14, 2025
- Accession no.
- 0001474506-25-000089
- Filed
- May 14, 2025, 5:52 PM ET
- Trade date
- May 12, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $2.00M. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001474506-25-000109 (Jun 11, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Inscobee Inc.CIK 0002057997 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2025 | Common Stock, par value $0.01 per share | PPurchaseAcquired | +500,000 | $4.00 | +$2,000,000 | 1,984,616 | Direct | |
| May 12, 2025 | Common Stock, par value $0.01 per share | CConversionAcquired | +182,002 | $2.60 | +$473,205.2 | 4,316,618 | Indirect | |
| May 12, 2025 | Common Stock, par value $0.01 per share | CConversionAcquired | +71,090 | $2.60 | +$184,834 | 4,387,708 | Indirect | |
| May 12, 2025 | Common Stock, par value $0.01 per share | CConversionAcquired | +44,041 | $2.60 | +$114,506.6 | 2,028,657 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2025 | Common Stock, par value $0.01 per share | CConversionDisposed | −182,022 | $0.00 | – | 0 | Indirect | |
| May 12, 2025 | Common Stock, par value $0.01 per share | CConversionDisposed | −71,090 | $0.00 | – | 0 | Indirect | |
| May 12, 2025 | Common Stock, par value $0.01 per share | CConversionDisposed | −44,041 | $0.00 | – | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.